FLECTOR (diclofenac epolamine) by IBSA Institut Biochimique is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2007.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
FLECTOR is a topical diclofenac epolamine patch approved in 2007 for localized pain and inflammation relief. It is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, thereby decreasing pain, inflammation, and fever. The transdermal delivery system allows direct application to affected areas with reduced systemic exposure.
Small commercial footprint with declining trajectory signals defensive positioning and likely reduced team expansion; focus will shift to retention and efficiency.
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries
Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain
Worked on FLECTOR at IBSA Institut Biochimique? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on FLECTOR offers exposure to end-of-life product management, defensive commercialization, and payer negotiations in a competitive, commoditized market. Roles available are primarily in sales support and market access rather than growth-oriented positions, making this suitable for professionals seeking stability and operational expertise rather than career acceleration.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo